Tags

Type your tag names separated by a space and hit enter

Safety overview of FDA-approved medications for the treatment of the motor symptoms of Parkinson's disease.
Expert Opin Drug Saf. 2014 Aug; 13(8):1055-69.EO

Abstract

INTRODUCTION

Parkinson's disease (PD) is among the most common of the neurodegenerative disorders. Treatment is primarily focused on correcting neurotransmitter imbalances. Several classes of medication are available for this purpose.

AREAS COVERED

A Medline search was performed to gather information about the safety of the medications approved for the treatment of the motor symptoms of PD. This was supplemented with additional articles obtained from online sources and information provided by the FDA and the manufacturers. The focus of this review is the side-effect and safety profiles of carbidopa/levodopa, dopamine agonists, selective monoamine oxidase inhibitors, catechol-o-methyltransferase inhibitors, anticholinergics and amantadine.

EXPERT OPINION

Though serious side-effects may occur, as a group, the medications used for the treatment of PD motor symptoms tend to produce side-effects that are mild to moderate in nature, and that primarily reflect the focus on dopaminergic therapies. Care plans for Parkinson's patients should be approached based on the needs of the individual as disease presentation, lifestyle, level of disability, concurrent disease states and the presence of non-motor symptoms make each case unique. Patients and caregivers must have realistic expectations about the use of PD medications.

Authors+Show Affiliations

Creighton University School of Pharmacy and Health Professions and School of Medicine , 2500 California Plaza, Omaha, NE 68178 , USA +1 402 280 3145 ; faulkner@creighton.edu.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

24962891

Citation

Faulkner, Michele A.. "Safety Overview of FDA-approved Medications for the Treatment of the Motor Symptoms of Parkinson's Disease." Expert Opinion On Drug Safety, vol. 13, no. 8, 2014, pp. 1055-69.
Faulkner MA. Safety overview of FDA-approved medications for the treatment of the motor symptoms of Parkinson's disease. Expert Opin Drug Saf. 2014;13(8):1055-69.
Faulkner, M. A. (2014). Safety overview of FDA-approved medications for the treatment of the motor symptoms of Parkinson's disease. Expert Opinion On Drug Safety, 13(8), 1055-69. https://doi.org/10.1517/14740338.2014.931369
Faulkner MA. Safety Overview of FDA-approved Medications for the Treatment of the Motor Symptoms of Parkinson's Disease. Expert Opin Drug Saf. 2014;13(8):1055-69. PubMed PMID: 24962891.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Safety overview of FDA-approved medications for the treatment of the motor symptoms of Parkinson's disease. A1 - Faulkner,Michele A, Y1 - 2014/06/24/ PY - 2014/6/26/entrez PY - 2014/6/26/pubmed PY - 2015/3/3/medline KW - Parkinson’s disease KW - amantadine KW - anticholinergics KW - catechol-O-methyltransferase KW - catechol-O-methyltransferase inhibitors KW - dopamine agonists KW - dyskinesia KW - levodopa KW - monoamine oxidase KW - monoamine oxidase inhibitors SP - 1055 EP - 69 JF - Expert opinion on drug safety JO - Expert Opin Drug Saf VL - 13 IS - 8 N2 - INTRODUCTION: Parkinson's disease (PD) is among the most common of the neurodegenerative disorders. Treatment is primarily focused on correcting neurotransmitter imbalances. Several classes of medication are available for this purpose. AREAS COVERED: A Medline search was performed to gather information about the safety of the medications approved for the treatment of the motor symptoms of PD. This was supplemented with additional articles obtained from online sources and information provided by the FDA and the manufacturers. The focus of this review is the side-effect and safety profiles of carbidopa/levodopa, dopamine agonists, selective monoamine oxidase inhibitors, catechol-o-methyltransferase inhibitors, anticholinergics and amantadine. EXPERT OPINION: Though serious side-effects may occur, as a group, the medications used for the treatment of PD motor symptoms tend to produce side-effects that are mild to moderate in nature, and that primarily reflect the focus on dopaminergic therapies. Care plans for Parkinson's patients should be approached based on the needs of the individual as disease presentation, lifestyle, level of disability, concurrent disease states and the presence of non-motor symptoms make each case unique. Patients and caregivers must have realistic expectations about the use of PD medications. SN - 1744-764X UR - https://www.unboundmedicine.com/medline/citation/24962891/Safety_overview_of_FDA_approved_medications_for_the_treatment_of_the_motor_symptoms_of_Parkinson's_disease_ L2 - https://www.tandfonline.com/doi/full/10.1517/14740338.2014.931369 DB - PRIME DP - Unbound Medicine ER -